Intrinsiqq
Pharming Group N.V. ADR logo

Pharming Group N.V. ADR Quality Score

PHAR

Compare
Quality56

Business quality is the primary weakness (avg 30/100). Growth is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
92.7x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
60/100
25.0x

25–30x, paying up for cash generation

Revenue Growth
100/100
15.5%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
13.8%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
14.4%

Heavy dilution above 5%

Margin Trend
20/100
-1.4pp

Modest contraction, within normal range

Capital Structure
100/100
-$63M

Net cash position, no leverage concern

2022
$207M
$167M
2023
$213M
$172M
2024
$168M
$112M
2025
$179M
$116M
CashDebt
Return on Capital
0/100
2.9%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Pharming Group N.V. ADR (PHAR) quality: score, margins and returns

Pharming Group N.V. ADR (PHAR) scores 56/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 3.4% operating margins and 2.9% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Pharming Group N.V. ADR (PHAR) a high-quality business?+

Pharming Group N.V. ADR scores 56 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 3.4% operating margin and a 2.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Pharming Group N.V. ADR's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from PHAR's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Pharming Group N.V. ADR scores well and where it falls behind.

What is Pharming Group N.V. ADR's return on invested capital (ROIC)?+

Pharming Group N.V. ADR earns about 2.9% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to PHAR's margins and growth on this scorecard to judge durability.

How profitable is Pharming Group N.V. ADR?+

Pharming Group N.V. ADR runs an operating margin of about 3.4% and a net margin of about 2.5%. Revenue has grown at roughly 16.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with PHAR

CompareIntrinsic value
M12.XETRM1 Kliniken AG
€18.62-4.51%91
CARA.XSTOCarasent AB
€2.14-0.70%54
PPGN.XSWXPolyPeptide Group AG
No recent price30
PAX.XSTOPaxman AB
€6.00+2.92%39
MLECMoolec Science SA
No recent price10
SKAN.XSWXSKAN Group AG
No recent price33
CANTA.XSTOCantargia AB
€0.08+0.24%54
EUZ.XETREckert & Ziegler SE
€14.48-1.83%74

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing PHAR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.